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Abstract
Stressful events have been implicated in the provocation of depressive illness. Inasmuch as immunological
challenge, and particularly cytokine administration, engender neuroendocrine and central neurochemical
changes reminiscent of those provoked by psychogenic stressors, it was suggested that immune activation
may also contribute to aﬀective illness. The present report provides a brief overview of the neurochemical
sequelae of acute and repeated interleukin-1b (IL-1b), tumour necrosis factor-a (TNF-a) and IL-2 treatment,
describes some of the synergisms associated with these treatments, as well as their potential interactions
with psychogenic stressors. In addition, a discussion is provided concerning the fact that cytokines, like
stressors, may have time-dependent proactive eﬀects, so that re-exposure to the treatments provoke greatly
augmented neurochemical changes (sensitization). Given that the eﬀects of cytokines are evident within
hypothalamic, as well as extrahypothalamic sites, including various limbic regions, it is suggested that
cytokines may impact on emotional changes, including depression.
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Introduction
Stressful events, coupled with the inability to cope
adequately with such insults, may be fundamental in
the provocation of aﬀective disorders (Griﬃths et al.,
2000), and may exacerbate or promote physical patho-
logies, including those related to cardiovascular illness
and immune dysfunction (Herbert and Cohen, 1993).
The ﬁndings that communication may occur between
the immune and central nervous systems (Blalock,
1984) prompted the proposition that depressionmaybe
inﬂuenced by immunological processes, just as psycho-
logical stressors have such an eﬀect. While several
potential routes of communication exist between the
immune and central nervous systems, it has been
suggested that cytokines, signalling molecules of the
immune system, may act as immunotransmitters
(Dunn, 2001). In this respect, cytokines engender cen-
tral neurochemical changes, much like those elicited
by psychological stressors (Anisman and Merali
1999; Dunn, 1993; 2001), thereby promoting aﬀective
disorders (Leonard, 2001; Maes, 1999). In addition to
their indirect eﬀects, central expression of several cyto-
kines may be elicited by stressors, various insults re-
lated to brain injury, and by endotoxin challenge, and
may thus impact on mood states. The present review
will argue that :
(1) Immune challenge (and particularly cytokine re-
lease), like stressful events, provokes central neuro-
chemical changes that favour the development of
aﬀective disturbances.
(2) Aﬀective disturbances are more likely to emerge
if an immune insult is superimposed on a back-
ground of stressful events (synergistic eﬀects).
(3) Stressors and cytokines may promote the sensiti-
zation of central neurochemical processes, andmay
thus proactively inﬂuence the response to sub-
sequently encountered insults.
Relation between stressors and aﬀective state
Depressive illness has been associated with antecedent
stressful life events (Abramson et al., 1978; Brown
and Harris, 1978; Brown et al., 1987; Monroe and
Depue, 1991; Paykel, 2001), including not only major
traumas, but also the accumulation of slight stressors
(Kanner et al., 1981). While the development of de-
pression may stem from the cognitive disturbances
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associated with stressful events or failure experiences
(Abramson et al., 1978), it is equally possible that
the aﬀective illness follows from the stressor-elicited
neurochemical alterations (Anisman et al., 1991; Weiss
and Simson, 1989).
The impact of stressor experiences appears to be
dependent upon experiential factors, the individual’s
ability to cope with the stressor through behavioural
means, and by the characteristics of the stressor itself
(e.g. severity, chronicity, predictability). Among other
things, these factors may inﬂuence the appraisal of the
stressor and the behavioural response to it (Lazarus,
1993), as well as neurochemical functioning (Anisman
et al., 1991). Additionally, the individual’s stressor
history (including early life trauma) may aﬀect the
subsequent response to a stressor, thereby inﬂuencing
vulnerability to illness (Brown and Harris, 1989; Roy,
1985). In this respect, it was suggested (Post, 1992)
that the neurochemical substrates of the illness may
evolve over time following stressor exposure and over
repeated illness episodes (sensitization eﬀects). Thus,
while earlydepressive episodesmaybe associatedwith
stressful events, once the neurochemical systems are
sensitized, even inocuous events may elicit adverse
outcomes (Kendler et al., 2000; Lewinsohn et al., 1999;
Solomon et al., 2000). As will be described shortly,
stressors and cytokine treatments share several com-
mon eﬀects, including the sensitization of neuro-
chemical systems. In light of the parallel eﬀects of these
treatments, the possibility ought to be considered that
activation of the inﬂammatory response system might
also inﬂuence aﬀective consequences of later stressor
encounters.
Stress, depression and neurochemical status
Depression has been attributed to a variety of neuro-
chemical disturbances, including alterations of nor-
epinephrine (NE), dopamine (DA) and serotonin
(5-HT), or their receptors (Maes and Meltzer, 1995;
Schatzberg and Schildkraut, 1995) as well as various
hormonal alterations (Plotsky et al., 1995). Coupled
with the disparate symptoms of the illness and the
variability in response to treatments, it is likely that
depression is a biochemically heterogeneous disorder,
wherein the substrates for the illness varies across
individuals.
It appears that aversive events induce several of
the central neurotransmitter alterations (e.g. variations
of NE, DA and 5-HT turnover and levels, as well as
receptor regulation) thought to subserve the depress-
ive syndrome. Moreover, many of the variables con-
sidered important in promoting human depression
(e.g. stressor controllability, predictability, chronicity),
inﬂuence stressor-provoked amine alterations in ani-
mals (Anisman et al., 1991; Weiss and Simson, 1989).
These neurochemical changes may be of adaptive sig-
niﬁcance, in that they may blunt the psychological or
physical impact of stressors, facilitate responses to deal
with the challenge (Anisman et al., 1991), and stimulate
processes which prevent excessive physiological acti-
vation (Munck et al., 1984).With continued exposure to
a stressor, compensatory increases of amine synthesis
may ensue, and concentrations of the amine may be
increased (Anisman et al., 1991;Deutch andRoth, 1990;
Herman and Cullinan, 1997; Irwin et al., 1986; Puglisi-
Allegra et al., 1991). Despite the presumed adaptive
consequences of the enhanced neuronal functioning,
it is thought that under such conditions the wear and
tear on the systemmay become excessive (e.g. allostatic
load), increasing vulnerability to pathology (McEwen,
1998). In this respect, it may be particularly appropriate
to evaluate the impact of chronic, unpredictable stres-
sors (including psychogenic, neurogenic and systemic
insults) on depressive states.
Cytokines as neuromodulators
Although cytokines are relatively largemolecules, they
may gain access to the brain and have direct actions on
CNS processes. In particular, interleukin-1b (IL-1b)
(Banks et al., 1989) and tumour necrosis factor-a
(TNF-a) (Gutierrez et al., 1993) have saturable carrier-
mediated transport mechanisms, which pump these
cytokines into the brain. Further, entry into the brain
may occur at circumventricular areas, which lack an
eﬃcient blood–brain barrier (BBB) (Banks et al., 1989;
Quagliarello et al., 1991), ultimately reaching various
brain nuclei through a process of volume diﬀusion
(Konsman et al., 2000; Laﬂamme and Rivest, 1999; Lee
et al., 1998). Interestingly, IL-1b and TNF-a them-
selves may disrupt the BBB (Quagliarello et al., 1991),
thereby increasing accessibility of the CNS. Paren-
thetically, the view was also expressed that cytokines
may aﬀect the BBB by the induction of adhesion mol-
ecules, such as ICAM-1 and VCAM-1 in the brain en-
dothelium and astrocytes, which may guide inﬂam-
matory leucocytes into the brain parenchyma (Merrill
and Benveniste, 1996). Moreover, cytokines and stres-
sorsmay increaseBBBpermability by increasing the ex-
pression of vasoactive and inﬂammatory factors, such
as cyclooxygenase-2 (COX-2; rate-limiting enzyme
for the synthesis of the pyrogenic, prostaglandins) and
histamine at cerbrovascular sites (Esposito et al., 2001;
Mark et al., 2001). Additionally, stressorsmay inﬂuence
the traﬃcking of cytokines into the brain parenchyma;
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as such challenges may also alter BBB permeability
(Esposito et al., 2001). Once present within the brain,
cytokines can provoke a functional response by bind-
ing to speciﬁc receptors at hypothalamic and extra-
hypothalamic brain regions (Cunningham and De
Souza, 1993; Kinouchi et al., 1991; Laﬂamme and
Rivest, 1999; Schobitz et al., 1994) or by other processes
that stimulate neurotransmitter functioning. Indeed,
both IL-1 and TNF-a may have functions similar to
classical neurotransmitters through their modulation
of neuronal Ca2+ channels and activation of intra-
cellular second-messenger systems (Tancredi et al.,
1992).
In response to systemic insults, cytokines and other
immune factors (such as endotoxin) can bind to the
endothelium of the brain microvasculature, which will
in turn produce signalling mediators, such as hista-
mine, nitric oxide (NO), nuclear factor kappa B (NFkB;
a signal transduction protein common to many cyto-
kines, including IL-1b and TNF-a) and COX-2 (Chao
et al., 1995; O’Connor and Coogan, 1999; Rivest et al.,
2000). Indeed, TNF-a was reported to increase hista-
mine, NFkB and COX-2 expression as well as pros-
taglandin release at cerebral endothelial capillaries
(Blais and Rivest, 2001; Igaz et al., 2001; Mark et al.,
2001). These mediators may be responsible for the
altered synthesis/activity of other cytokines, neuro-
transmitters and hormones as well as central metabolic
processes. For instance, elevated central prostaglandins
may stimulate hypothalamic–pituitary–adrenal (HPA)
activity and provoke febrile responses (Parsadaniantz
et al., 2000; Roth et al., 2002). Additionally, through
induction of these factors, and perpetuation of the in-
ﬂammatory response, pro-inﬂammatory cytokinesmay
inﬂuence cellular plasticity and neurodegeneration.
In fact, chronic stressors have recently been suggested
to promote neurodegeneration through activation of a
TNF-a cascade involving increased NFkB expression
and downstream activation of NO (Madrigal et al.,
2002).
In addition to direct actions, cytokinesmay inﬂuence
CNS processes indirectly through stimulation of aﬀer-
ent ﬁbres of the vagus nerve (Dantzer et al., 1996;Maier
and Watkins, 1998; Watkins et al., 1995). Receptors for
IL-1 are present on the nodose ganglion which sends
aﬀerent projections to the brainstem nucleus tractus
solitarius (NTS), and following cytokine or endotoxin
challenge, c-fos expression is elevated in these regions
(Ek et al., 1998; Gaykema et al., 1998). It appears that
activation of vagal branchesmay stimulate the de-novo
synthesis of cytokines within brainstem and hypo-
thalamic nuclei (Dantzer et al., 2001; Gaballec et al.,
1995; Hopkins and Rothwell, 1995).
Central cytokine distribution and the impact of
varied challenges
Although their levels in brain are admittedly lowunder
basal conditions, cytokines and their receptors are en-
dogenous to the brain, having been identiﬁed within
neuronal cell bodies, microglia and astrocytes
(Cunningham and De Souza, 1993; Kinouchi et al.,
1991; Laﬂamme andRivest, 1999;Nistico andDe Sarro,
1991). Levels of cytokines and their receptors are in-
ﬂuenced by various stressors as well as by immuno-
logical and neurological insults. For instance, IL-1b
protein levels were increased in several brain regions
in response to stressors (Nguyen et al., 1998, 2000).
Moreover, elevated IL-1b, IL-6 and/or TNF-a mRNA
was observed in the CNS following immobilization
stress (Minami et al., 1991; Yabuuchi et al., 1996), sys-
temic lipopolysaccharide (LPS) administration (Ban
et al., 1992; Breder et al., 1994; Buttini and Boddeke,
1995; Gaballec et al., 1995; Gatti and Bartfai, 1993; Laye
et al., 1994; Liu et al., 1996), central LPS injection (De
Simoni et al., 1995; Quan et al., 1994; Rajora et al., 1997),
viral infection (Sato et al., 1997), brain injury, tumours,
cerebral ischaemia and seizure (Buttini et al., 1994;
Giulian and Robertson, 1990; Hopkins and Rothwell,
1995; Ilyin et al., 1999; Minami et al., 1990; Rothwell
and Hopkins, 1995; Taupin et al., 1993; Yabuuchi et al.,
1993). Further, peripherally administered cytokines
may even stimulate their own expression within the
brain, thus potentially placing these molecules in the
vicinity of their receptors (Butinni and Boddeke, 1995;
Cunningham and De Souza, 1993). Parenthetically, it
will be recognized that some of the aforementioned
insults were essentially of an acute nature, while others
involved chronic repercussions. At present, insuﬃcient
information exists concerning the relative eﬀects of
acute and chronic stressors on central cytokine activity.
Elevated central cytokine levels in response to in-
sults have been associated with neurological and be-
havioural changes, including somnolence (Krueger
et al., 1998), cognitive disturbances (Fiore et al., 1996),
and disruptions of eating as well as cachexia (Plata-
Salama´n, 1998). Similarly, these signs are evident in
response to exogenous central cytokine application.
The severity of these signs depends on the nature,
chronicity andmagnitude of the challenge, all of which
will inﬂuence central levels of cytokines.
In considering the central actions of the pro-inﬂam-
matory or stimulatory cytokines, it should be con-
sidered that anti-inﬂammatory or inhibitory signals are
also present, including IL-4, IL-10 (Szczepanik et al.,
2001), IL-1 receptor antagonist (IL-1Ra) (Licinio and
Wong, 1997) as well as soluble receptors for IL-1b
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(Colotta et al., 1994) and TNF-a (Shohami et al., 1999).
It is not the level of pro-inﬂammatory cytokine, per se,
that determines the impact of cytokine activation in
the brain, but the balance between the pro- and anti-
inﬂammatory signals (Licinio and Wong, 1997; Plata-
Salaman et al., 1998). Additionally, since most stimu-
latory cytokine receptor-bearing cells need only a
few ligands to become biologically active, a substantial
accumulation of their inhibitory counterparts will be
needed to suppress the activating signal. In eﬀect,when
evaluating immune insults, it ought to be considered
that the magnitude and chronicity of the challenge will
impact on the neurological manifestations associated
with cytokine activation. Highly toxic challenges (e.g.
LPS) and chronic ailments (e.g. tumours) will shift
the balance toward the pro-inﬂammatory cytokines
and promote more detrimental consequences (Plata-
Salaman et al., 1998), whilemilder and acute challenges
(e.g. single, low doses of a cytokine) will shift the bal-
ance toward the anti-inﬂammatory cytokines and have
more subdued repercussions.
Cytokine-induced activation of the HPA axis
Like stressors, various immunogenic and cytokine
challenges (e.g. LPS and IL-1b) stimulate HPA activity
(Brebner et al., 2000; Del Rey and Besedovsky, 1992;
Dunn, 1992; Turnbull and Rivier, 1999). Systemic and
intracerebroventricular (i.c.v.) IL-1b administration
increased c-fos expression within the paraventricular
nucleus (PVN) of the hypothalamus corticotropin-
releasinghormone (CRH)neurons (Ericssonet al., 1994;
Vellucci et al., 1995) and increased the expression of
CRH and arginine vasopressin (AVP) secretion in PVN
neurons of the hypothalamus (Lee and Rivier, 1994;
Mandrup-Poulsen et al., 1995; Tilders et al., 1993).
Moreover, IL-1b infusion into the median eminence
(site of CRH terminals fromneurons originatingwithin
the PVN) increased AVP and CRH secretion and pro-
voked elevated plasma adrenocorticotropic hormone
(ACTH) and corticosterone levels (McCoy et al., 1994;
Watanobe and Takebe, 1993). Predictably, CRH anta-
gonists attenuated the IL-1b-induced ACTH changes
(Saperstein et al., 1992). While, the eﬀects of IL-1b on
HPA activity have primarily been assessed in acute
preparations, continuous systemic infusion (via os-
motic minipumps) of this cytokine over 1 wk provoked
a persistent increase of plasma ACTH and corticoster-
one levels (Sweep et al., 1992). Moreover, as will be
discussed later, acute and chronic systemic IL-1b ad-
ministration may result in a long-lasting increase of
CRH and AVP co-expression within the external zone
of themedian eminence, and thusmay have protracted
repercussions with respect to the impact of later chal-
lenges (Tilders and Schmidt, 1998). Finally, in addition
to IL-1b, HPA activity was increased by other pro-
inﬂammatory cytokines, including IL-6 and TNF-a
(Bernardini et al., 1990; Brebner et al., 2000; Dunn,
2001; Hayley et al., 1999; Rothwell and Hopkins, 1995;
Zhou et al., 1996), and these eﬀects were blocked by
CRH antiserum (Bernardini et al., 1990; Turnbull et al.,
1997).
Central neurochemical eﬀects elicited by activation
of the inﬂammatory response system or cytokine
challenge
Although the central neurotransmitter eﬀects of vari-
ous cytokines have been assessed, greatest attention
has been devoted to the impact of IL-1b. Following
its systemic administration, IL-1b stimulated c-fos ex-
pression in several stressor-sensitive brain regions,
including the PVN, bed nucleus of the stria terminalis,
and central nucleus of the amygdala (Day et al., 1999;
Ericsson et al., 1997; Xu et al., 1999). Moreover, this
treatment increased NE activity within the PVN, me-
dial basal and lateral hypothalamic nuclei (Dunn,
2001; Kaur et al., 1998; Lacosta et al., 1998a,b), and
increased DA utilization within the hypothalamus
and prefrontal cortex (Kabiersch et al., 1988; Masana
et al., 1990) and 5-HT activity within the hypo-
thalamus, prefrontal cortex and hippocampus (Brebner
et al., 2000; Carmelia et al., 1991; Dunn, 2001; Zalcman
et al., 1994). In vivo, systemic IL-1b administration
increased hypothalamic NE and 5-HT release from the
nucleus accumbens and the hippocampus, respectively
(Merali et al., 1997; Smagin et al., 1996; Song et al.,
1999).
Paralleling the actions of systemic treatment, i.c.v.
IL-1b increased hippocampal 5-HT release (Linthorst
et al., 1995), while direct application of IL-1b into the
rat anterior hypothalamus increased the release of NE,
5-HT and DA (Shintani et al., 1993). Similarly, when
directly injected into the medial basal hypothalamus,
IL-1b augmented 5-HT and DA release (Mohankumar
and Quadri, 1993; Mohankumar et al., 1993), and local
injection of IL-1b increased NE release within the
medial prefrontal cortex (Kamikawa et al., 1998).
Like IL-1b, systemic TNF-a administration also in-
creased central monoamine activity, including NE and
5-HT activity within the PVN, central amygdala, locus
coeruleus and prefrontal cortex (Hayley et al., 1999),
and altered tryptophan levels within the hippocam-
pus and hypothalamus (Dunn, 2001; Leonard, 2001).
Similarly, i.c.v. TNF-a stimulated amine turnover,
particularly within hypothalamic nuclei (PVN and
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median eminence/arcuate nucleus) (Hayley et al., In
Press).
Most of the studies described thus far have pointed
to cytokine treatment provoking increase monoamine
release. Yet, it will be recognized that depressive ill-
ness has typically been considered to reﬂect a down-
regulation of monoamine functioning. However, two
issues need to be considered in relating the eﬀects of
cytokine treatments to depression. First, in addition to
aﬀecting monoamine release, it was reported that,
in vitro, IL-1 provokes activation of the 5-HT trans-
porter, thus enhancing reuptake of 5-HT from the
synaptic cleft (Ramamoorthy et al., 1995). Thus, the
availability of 5-HT may be diminished, depending on
the cytokine dosage.
Secondly, the aforementioned studies assessed the
consequences of acute cytokine administration. There
is presently insuﬃcient information available concern-
ing the impact of chronic cytokine treatment on neuro-
endocrine and central neurotransmitter functioning,
and limited data are available concerning the proactive
eﬀects of cytokines on neurochemical activity. This is
particularly critical, as immune activation stemming
from bacterial or viral insults, as well as cytokine
immunotherapy, involve sustained and persistent
alterations of cytokine activity. Thus, to obtain a more
realistic index of the eﬀects relevant to depression, it
may bemore productive to assess the impact of chronic
activation of the inﬂammatory response system or re-
peated administration of cytokines. It has been shown
that sustained systemic or i.c.v. IL-1b administration
provokes marked and persistent HPA activation
(Sweep et al., 1992; Van der Meer et al., 1996) while
chronic central IL-1b administration promotes activa-
tion of hypothalamic–pituitary–gonadal axis (Rivest
et al., 1993). Indeed, chronic IL-1b administration pro-
moted sustainedvariations ofCRH,CRH receptors and
pro-opiomelanocortin gene expression coupled with
elevated secretion of ACTH, b-endorphin and cortico-
sterone (Parsadaniantz et al., 1997). Importantly, it
was also shown that continuous intravenous infusion
of IL-1b not only augmented c-fos expression within
speciﬁc hypothalamic nuclei (PVN and supraoptic
nucelus), but also provoked such eﬀects within the
central amygdala. While the hypothalamic eﬀects were
attenuated by pretreatment with a cyclo-oxygenase
inhibitor, this was not the case within the central
amygdala (Niimi et al., 1996). Thus, hypothalamic and
amygdala alterations likely involve diﬀerent mechan-
isms. At any rate, the ﬁnding that chronic cytokine
treatments may have protracted repercussions is con-
sistent with the elevated HPA activity evident in some
forms of depression. However, it is still not certain
what immediate or protracted eﬀects are induced by
chronic cytokine treatments on the activity of mono-
amines that are believed to contribute to aﬀective
illness.
Owing to the redundancies and pleiotropic nature of
cytokine networks, it is important not only to consider
their individual eﬀects, but also to determine the in-
teractive eﬀects of cytokines on central processes. In
particular, cytokines may act in a synergistic fashion,
such that their co-administration results in eﬀects
greater than the sum of their individual eﬀects. In fact,
co-administration of either TNF-a and IL-1b or IL-6
and IL-1b provoked a synergistic increase of HPA, but
not central monoamine, activity (Brebner et al., 2000;
Perlstein et al., 1993; Zhou et al., 1996). Interestingly,
cytokines and stressors may also have synergistic ef-
fects, as observed with respect to the in-vivo release of
5-HT from mesolimbic brain sites (Merali et al., 1997).
In particular, it has been shown that the increased in-
vivoNE and 5-HT releasewithin the hippocampus and
nucleus accumbens elicited by IL-1b was greatly aug-
mented following the application of a mild stressor
(air puﬀ) (Merali et al., 1997; Song et al., 1999). More-
over, in chronically stressed animals the administration
of LPS promoted a greater IL-1 response, although this
eﬀect was not necessarily accompanied by elevated
ACTH or corticosterone secretion (Mekaouche et al.,
1994).Nevertheless, it seems reasonable to suppose that
synergisms may occur between stressor and cytokine
treatments, as they do between diﬀerent cytokines, so
that the response of endogenous neurochemical sys-
tems will be exaggerated. Incidentally, it might be
noted at this juncture that the behavioural eﬀects of
cytokine treatments may be altered by environmental
stimuli, particularly those contextual cues that in-
volve a stressful component. For instance, reactivity
in response to the T-cell superantigen, staphylococcal
enterotoxin B, was enhanced by exposure to novel
stimuli (Kawashima and Kusnecov, 2002), and IL-2
similarly provoked behavioural activation in response
to a novel stimulus (Zalcman et al., 1998, Zalcman,
2001), and increased locomotor activity under anxiety-
provoking conditions (on a plus maze) (Petitto et al.,
1997). Similarly, the sickness-inducing eﬀects elicited
by cytokines, such as IL-1, may not be evident in novel
environments, particularlywhen this environmentwas
stressful (Lacosta et al., 1999). Thus, we argued that
while cytokines could produce marked illness, in a
novel environment that may signal danger, animals do
not have the luxury of expressing sickness behaviours.
In a like fashion, one can imagine that the anhedonic
or depressogenic action of cytokines may be context-
dependent.
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As indicated earlier, it has been proposed that
depressive mood results when monoamine utilization
exceeds synthesis, resulting in insuﬃcient amine con-
centrations tomeetdemandsexertedbyneworongoing
stressors. In a similar fashion, it ought to be considered
that following chronic activation of the inﬂammatory
response system the eﬀects of stressors may be aug-
mented, and moreover in chronically stressed animals
the central eﬀects of cytokine or immune challenges
may be appreciably enhanced, thereby favouring the
development of mood disturbances.
The role of cytokines in the stress response:
immune activation as a stressor
Asalreadyindicated, ‘processive ’stressors (i.e.psycho-
genic or neurogenic stimuli or events that involve ap-
praisal processes or higher order sensory cortical
processing) share several eﬀects with those elicited by
systemic (metabolic) insults, such as bacterial or viral
infection (Herman andCullinan, 1997).While, diﬀerent
neural circuits are activated in response to processive
and systemic stressors, these insults trigger some com-
mon end points, such as HPA activation. It was sug-
gested that while processive stressors engender such
outcomes via activation of limbic mechanisms, sys-
temic stressors may have more direct eﬀects through
actions at the hypothalamus (Herman and Cullinan,
1997). Indeed, exposure to a novel environment (pro-
cessive stressor) increased c-fos mRNA within limbic
regions (e.g. lateral septum and medial amygdaloid
nucleus) to a much greater extent than did inhalation
of ether vapours (systemic stressor), although both
stressors had comparable eﬀects within the hypo-
thalamus (Emmert and Herman, 1999). Further, while
footshock and cytokine challenge were both shown
to increase c-foswithin the PVN, catecholamine dener-
vation was only eﬀective in attenuating the eﬀects of
the cytokine treatment (Li et al., 1996). Similarly, the
HPA-stimulating eﬀects of IL-1b were attenuated by
ablation of aminergic ﬁbres originating from the med-
ulla or removal of the area postrema (a brainstem,
circumventricularorgan) (Ericssonetal., 1994;Leeetal.,
1998). Interestingly, Shintani et al. (1995) demonstrated
that pretreatment with IL-1Ra, blocked the hypotha-
lamic NE alterations and the plasma ACTH increases
induced by immobilization, suggesting that cytokines
may play a role in the regulation of the stress response
elicited by processive types of stressors.
In relating the eﬀects of stressors and cytokines to
emotional states, it is important to consider the eﬀects
on limbic regions that have been implicated in anxiety
and depression (e.g. the amygdala and prefrontal
cortex). It appears likely that diﬀerent nuclei of the
amygdala, and particularly CRH neuronal activity
within these sites, contributes to the maintenance of
anxiety (LeDoux, 2000). In this respect, the basolateral
nucleus of the amygdala may play a prominent role
in the initial processing of fearful stimuli, while the
central nucleus may be more important for the gener-
ation of behavioural outputs to contend with the
challenge (Davis, 1992). Consistent with a role of IL-1b
in promoting anxiety-related responses (Anisman and
Merali, 1999), it was reported that as in the case of
psychogenic stressors, IL-1b increased CRH mRNA
expression at the amygdala and bed nucleus of the
stria terminalis (Day et al., 1999; Lee and Rivier, 1998;
Makino et al., 1999; Sawchenko et al., 1996). Moreover,
lesions of the central amygdala attenuated the plasma
corticosterone and ACTH responses elicited by IL-1b,
supporting the possibility that amygdaloid–PVN com-
munication may be important in regulating cytokine-
elicited HPA responses (Xu et al., 1999).
While these data point to the similarity between the
eﬀects of stressors and immunogenic stimuli, it seems
that stressors and cytokines may activate diﬀerent re-
gions of the amygdala. Ericsson et al. (1994) reported
profound c-fos activation of the central amygdala in
response to footshock, while systemic IL-1b provoked
the strongest eﬀect within the medial nucleus. Little
information exists concerning the role of the medial
amygdala in the response to cytokines, relative to those
elicited by stressors; however, it was suggested that the
medial nucleus may play a more important role than
the central nucleus in the neuroendocrine response to
restraint stress (Dayas et al., 1999). Given that cytokines
and stressors may contribute diﬀerentially to amygda-
loid stimulation, these challenges may aﬀect diﬀerent
phases of anxiety/fear responses.
Although cytokines inﬂuence amygdala neuronal
activity, there is limited information concerning the
anxiogenic eﬀects of cytokine treatments. The i.c.v.
administration of IL-1b or TNF-a elicited anxiogenic-
like eﬀects, but this has been evaluated in only a limited
number of situations (Connor et al., 1998). Moreover, it
is not clear that the anxiety-like eﬀects associated with
IL-1b treatment stemmed from the central actions eli-
cited by the cytokine, and instead may have been sec-
ondary to the malaise engendered by the treatment.
Cytokine and stressor sensitization eﬀects
In addition to their immediate behavioural and neuro-
chemical eﬀects, stressful events may inﬂuence the
organism’s responses to later challenges. In fact, a
variety of stressors, including immunological stimuli,
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prime biological systems so that an augmented re-
sponse is elicited by later exposure to the same or
somewhat diﬀerent challenge (sensitization) (Anisman
et al., 2001; Tilders and Schmidt, 1998). As indicated
earlier, the development of a stressor-elicited sensiti-
zation eﬀect is believed to have important repercus-
sions for behavioural pathology, particularly with re-
spect to the recurrence of depression (approx. 30–50%
of patients suﬀer recurrence within 1 yr). Given that
cytokines may induce neurochemical eﬀects similar to
those provoked by processive stressors, it ought to be
considered that cytokine alterations (and sensitization
to the eﬀects of cytokines) might similarly contribute to
depressive episodes.
Stressor eﬀects
Stressor-provoked sensitization eﬀects have been de-
monstrated with respect to NE activity within the
hypothalamus, hippocampus and amygdala, and DA
utilization within the prefrontal cortex (Anisman et al.,
1991; Finlay et al., 1997; Jordan et al., 1994). Also,
cross-sensitization has been demonstrated wherein
exposure to a particular stimulus enhances the res-
ponse to a subsequently applied stimulus of a diﬀerent
form, including pharmacological challenges (Anisman
et al., 1993; Finlay et al., 1997; Flores et al., 2000; Gresch
et al., 1994; Hayley et al., 1999; Tilders and Schmidt,
1998). Like acute challenges, chronic stressors inﬂuence
responses to subsequent stressor encounters. In ani-
mals exposed to a chronic cold stressor regimen, later
application of tail shock augmented NE release within
the hippocampus and prefrontal cortex andDA release
from cortically projecting neurons (Gresch et al., 1994;
Jedema et al., 1999; Nisenbaum and Abercrombie,
1992).
As in the case of amine variations, stressors may
have protracted eﬀects onHPA functioning. It has been
suggested that such changes stem from phenotypic
alterations of CRH terminals within the median emi-
nence, wherein co-localization of AVP andCRH occurs
(Bartanusz et al., 1993). Speciﬁcally, a chronic stressor
regimen has been shown to provoke a progressive in-
crease ofAVP stores in theseCRH terminals (Bartanusz
et al., 1993; de Goeij et al., 1992a,b; Schmidt et al., 1995).
As CRH and AVP synergistically stimulate pituitary
ACTH release, the neuroendocrine response to sub-
sequent challenges ought to be increased.
Cytokine sensitization: HPA eﬀects
Cytokines, such as IL-1b and TNF-a, provoke behav-
ioural and neurochemical sensitization eﬀects, just
as traditional stressors do. These cytokines provoke
the sensitization of HPA activity such that later
re-exposure to the cytokine resulted in augmented
neuropeptide and hormonal activity. Interestingly,
the emergence the sensitization was dependent on the
passage of time following the initial challenge (Hayley
et al., 1999, 2001a; Schmidt et al., 1995). In particular,
while the cytokines increased the co-localization of
CRH and AVP within the median eminence, this out-
come only became apparent 4 d after IL-1b adminis-
tration and peaked 1–2 wk following the treatment
(Schmidt et al., 1995). A second administration of IL-1b
(11 d after the initial challenge) elevated plasma ACTH
and corticosterone levels (Schmidt et al., 1995), sug-
gesting that the cytokine provoked a functionally
hyper-responsive HPA axis.
Systemic administration of TNF-a also induced a
time-dependent sensitization of HPA activity. How-
ever, the temporal proﬁle of induction of the hypo-
thalamic peptide immunoreactivity did not parallel the
expression of the corticosterone sensitization. Speciﬁ-
cally, while median eminence CRH and AVP immuno-
reactivities were maximally elevated 7–14 d following
the initial TNF-a injection, the neuropeptide expression
was comparable to baseline by 28 d (Hayley et al.,
2001a). However, re-exposure to TNF-a 28 d following
initial administration of the cytokine provoked a pro-
nounced sensitization of corticosterone release, an
eﬀect that was absent at earlier re-exposure intervals
(1, 7 and 14 d) (Hayley et al., 1999). Thus, factors in
addition to hypothalamic CRHandAVPmay inﬂuence
the TNF-a-induced hormonal sensitization. For in-
stance, the cytokine may have had direct actions upon
the adrenal or pituitary gland, both of which contain
high TNF-a receptor densities (Kobayashi et al., 1997).
Similarly, other peripherally acting inﬂammatory fac-
tors (e.g. histamine) may mediate some of the sensi-
tizing eﬀects of TNF-a. Indeed, we recently observed
that systemic antihistamine treatment (H1 and H2
antagonists) ameliorated both the corticosterone and
sickness sensitization eﬀects of TNF-a (Kelly et al.,
2001). As well, in animals treated with TNF-a, later
i.c.v. re-exposure to the cytokine did not sensitize HPA
activity, irrespective ofwhether the initial injectionwas
centrally or peripherally administered, suggesting that
peripheral factors and/or targets are involved (Hayley
et al., 2002).
It is important to note that mice displaying the
TNF-a-induced HPA sensitization also showed signs
of marked illness (e.g. ptosis, piloerection, lethargy,
cyanosis of the extremities) (Hayley et al., 2001b). Al-
though it is tempting to speculate that stress or other
factors associated with the illness may be related to
the provocation of the corticosterone sensitization, we
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observed that that the two processes were independent
of one another (Hayley et al., 2001b).
Cytokine sensitization: central monoamine
alterations
In addition to the immediate neurotransmitter eﬀects,
re-exposure to TNF-a augmented monoamine activity
in a region-speciﬁc and time-dependent fashion
(Hayley et al., 1999, 2002). Within the PVN, TNF-a
induced a sensitization of NE activity, which followed
a time-course similar to that observed with respect to
the corticosterone and sickness sensitization eﬀects,
becoming progressively more pronounced at longer
intervals following initial cytokine treatment (Hayley
et al., 1999). In contrast, the sensitization of NE activity
within the prefrontal cortex and central amygdala was
evident at 1 d following the initial treatment with the
cytokine, but not at longer intervals. However, a TNF-a
provoked sensitization of 5-HT activity was apparent
within the central amygdala andprefrontal cortexupon
re-exposure to the cytokine after an intermediate in-
terval (7–14 d) following pretreatment (Hayley et al.,
1999), paralleling the increased CRH–AVP co-localiza-
tion within themedian eminence (Hayley et al., 2001a).
Although i.c.v. TNF-a did not sensitize cortico-
sterone activity, this treatment did elicit a sensitization
of NE and DA utilization within the PVN and median
eminence/arcuate nucleus complex (ME/ARC).More-
over, mice that initially received intraperitoneal (i.p.)
mTNF-a and later challenged via i.c.v. administration
with thiscytokinedisplayedgreatly increased5-HTand
DA activitywithin theME/ARC, aswell as augmented
NE activity within the locus coeruleus. Interestingly,
unlike the eﬀects of peripheral cytokine administration,
when administered i.c.v., the sensitization occurred
largelywithinhypothalamicnuclei (Hayleyet al., 2002).
Cytokines and depression
Major depression in humans, particularly in patients
presenting with severe melancholic illness, has been
associated with variations of immune functioning, in-
cluding a reduction ofmitogen-stimulated lymphocyte
proliferation and reduced natural-killer (NK) cell
activity (Herbert and Cohen, 1993; Irwin, 1999; Maes,
1995, 1999). Contrary to the position that depression
was associated with the suppression of non-speciﬁc
immunity, the view was advanced that aﬀective dis-
turbancesmay be secondary to activation of the inﬂam-
matory immune response (Licinio and Wong, 1997;
Maes, 1995, 1999). In this respect, depressed patients
were found to present with signs of immune activation
reminiscent of an acute phase response, including in-
creasedplasmaconcentrationsof complementproteins,
C3 and C4, IgM, and positive acute phase proteins,
haptoglobin, a1-antitrypsin, a1 and a2 macroglobulin,
whereas negative acute phase proteins were reduced
(Maes, 1999; Nieto et al., 2000; Rothermundt et al.,
2001; Sluzewska, 1999). Further, major depressive ill-
ness was accompanied by elevated activated T cells
(CD25+ and HLA-DR+), secretion of neopterin, pro-
staglandin E2 and thromboxane (Maes, 1995, 1999).
Parenthetically, although cortisol has often been shown
to be immunosuppressive, the changes in immune cell
populations are correlated with elevated urinary cor-
tisol levels (Maes et al., 1994). Interestingly, in a dexa-
methasone suppression test, non-supressors were also
resistant to the immune eﬀects of dexamethasone
(Maes et al., 1994), suggesting that the absence of
negative feedback by cortisol on the HPA axis in de-
pression could extend to the dysregulation in the levels
of immune markers observed in the condition.
Commensurate with the view that cytokines are
fundamental in depression, it was reported that severe
aﬀective illness was accompanied by elevated circu-
lating cytokines or their soluble receptors, including
IL-2, soluble IL-2 receptors (sIL-2R), IL-1b, IL-1Ra,
IL-6, soluble IL-6 receptors (sIL-6R), and c-interferon
(c-IFN) (Berk et al., 1997; Frommberger et al., 1997;
Maes, 1995, 1999; Mullar and Ackenheil, 1998; Nass-
berger and Traskman-Bendz, 1993; Sluzewska et al.,
1995; Smith, 1991; Song et al., 1994) aswell as increased
production of IL-1b, IL-6 and TNF-a in response to
mitogen challenge (Anisman et al., 1999a,b;Maes, 1995,
1999). Interestingly, with alleviation of depression in
response to antidepressant treatment, normalization
was evident with respect to levels of IL-1b, IL-6 and
a1-acid glycoprotein (Frommberger et al., 1997; Slu-
zewska et al., 1995), whereas no such changes were
apparent concerning the up-regulated production of
sIL-2R, IL-6 and sIL-6R in major depression (Maes,
1999). Similarly, antidepressant treatment did not dim-
inish the elevated serum levels of the IL-6, or that of
anti-inﬂammatory cytokines, IL-10 and IL-1Ra (Kubera
et al., 2000). In eﬀect, these cytokines may act simply as
traitmarkers of the illness (Anisman et al., 1999b;Maes,
1999), although it ought to be considered that sustained
treatment may be necessary to achieve normalization
of cytokine functioning.
The aforementioned studies, in the main, are corre-
lational, and thus it cannot be determined whether
the cytokine elevations are secondary to the illness (i.e.
being directly or indirectly brought on by the depres-
sion), or contribute to the provocation of the disorder.
Yet, it has been reported that in humans undergoing
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immunotherapy high doses of IL-2 and IFN-a induce
neuropsychiatric symptoms, including depression. As
such, these data imply that the aﬀective changes were
related to the cytokine treatment (Capuron et al., 1998;
Caraceni et al., 1992; Denicoﬀ et al., 1987; Maes et al.,
2001; Meyers and Valentine, 1995). Importantly, it was
reported (Musselmanetal., 2001) thatdepressive symp-
toms provoked by IFN-awere attenuated by treatment
with the selective serotonin reuptake inhibitor, parox-
etine. Together, these ﬁndings provide good reason to
suspect an aetiological role for cytokines in depressive
illness. Yet, it is important to consider that the popu-
lations being assessed in the latter studies were un-
dergoing considerable strain (e.g. the distress regard-
ing their illness), and hence depression may reﬂect the
interactive eﬀects of the distress and the cytokine
treatments.
TNF-a signalling and depression
Recent clinical studies have suggested that elevated
circulating TNF-a or its p55 receptor may be associated
with psychiatric illness (Maes, 1999) and such an eﬀect
could come about by virtue of the cytokine’s eﬀects on
central monoamine turnover (Ignatowski et al., 1997).
Indeed, antidepressant medication has been reported
to alter levels of TNF-a in brain regions such as the
hippocampus and locus coeruleus (Ignatowski et al.,
1997). Commensurate with the proposition that TNF-a
may be involved in stressor- or depressive-like states,
we found that TNF-a sensitized expression of the im-
mediate early gene, c-fos, in several stressor-sensitive
brain regions. Speciﬁcally, re-exposure to the cytokine
7 or 14 d following its initial i.p. pretreatment resulted
in a pronounced increase of Fos immunoreactive pro-
tein within the PVN, supraoptic nucleus and central
amygdala.
The fact that TNF-a sensitized 5-HT activity within
stressor-sensitive brain regions (Hayley et al., 1999,
2002) may reﬂect cytokine-provoked neuroplastic
changes, which may be reminiscent of those thought
to characterize clinical depression (Altar, 1999; Manji
et al., 2001). Further to this point, recent studies suggest
that major aﬀective disorders probably involve alter-
ations in pathways typically activated by cytokines
(Chen et al., 2001). In particular, the mitogen-activated
protein (MAP) kinase pathway, which is involved in
cytokine signalling [e.g. IL-6, brain-derived neuro-
trophic factor (BDNF)], as well as pathways involving
the cAMP response-binding element (CREB) factor,
which has important neuroplastic eﬀects, are both pro-
posed to play a role in the long-term neurochemical
changes evident in depression (Guillin et al., 2001).
Indeed, while stressors (which may be associated with
the provocation of depression) reduce the expression of
neurotrophic products of these pathways, antidepress-
ants stimulate these trophic factors. For instance,
chronic antidepressant treatments increased the cen-
tral expression of cAMP and CREB and some of their
target genes, including the neurotrophic cytokine,
BDNF (Vaidya and Duman, 2001). Moreover, stressor-
induced reductions of central BDNF levels were
ameliorated by antidepressant pretreatment (Vaidya
and Duman, 2001). Supporting a direct beneﬁcial role
for neurotrophic cytokines in depression, infusion of
either BDNF or the closely related neurotrophin-3
(NT-3) into the dentate gyrus produced an antide-
pressant eﬀect, as assessed in animal models of de-
pression (forced swim and learned helplessness), that
was comparable to that provoked by traditional chemi-
cal antidepressants (Shirayama et al., 2002). In human
post-mortem studies, increased hippocampal BDNF
expression was associated with chronic antidepress-
ant regimens (Chen et al., 2001). Thus, it may be useful
to consider alternate antidepressant treatments that
aﬀect BDNF or other trophic factors that may engender
a certain degree of protection or resilency of mono-
aminergic cells in the face of everyday stressors. In
particular, it is signiﬁcant that the recent report by
Shirayama et al. (2002) indicated that a single bilateral
infusion of BDNF had antidepressant eﬀects similar to
that provoked by a chronic antidepressant regimen.
The possibility exists that traditional antidepressants
come to exert their beneﬁcial eﬀects only after neutro-
phic factors and related messenger pathways have
been suﬃciently ‘primed’. If this is the case, then alter-
nate neurotrophic antidepressants may circumvent the
problem of long-term daily administration required
for traditional antidepressant eﬃcacy.
Stimulation of these cAMP and MAPkinase-depen-
dent pathways can also induce the anti-apoptotic fac-
tor, bcl-2, which has been suggested to have beneﬁcial
actions in depressive disorders (Chen et al., 2000;Manji
et al., 2001), just as it has a neuroprotective role in
neurodegenerative states (Guillin et al., 2001). With
respect to cytokines and depression, it appears that
TNF-a provokes bcl-2 expression, as well as pro-
apoptotic factors, suggesting that a delicate balance
between the expression of death regulatory signals
may ultimately determine the consequences of the
cytokine, with respect to cellular survival and resili-
ency. It may be the case that TNF-a priming induces
changes in these intracellular pathways (e.g. phos-
phorylation states) that ‘set the stage’ for the aberrant
neurochemical responses to subsequent challenges that
impinge upon this sensitized system.
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Conclusions
It seems likely that behavioural and neurochemical
plasticity is essential for an animal to cope with en-
vironmental demands. Various challenges, including
stressful and immunological stimuli, may provoke
central neurochemical alterations that may be of adapt-
ive signiﬁcance. Yet, some of these eﬀects may also
increase vulnerability to behavioural disturbances,
particularly mood disorders. Further, it appears that
both stressors and activation of the inﬂammatory re-
sponse system may prime biological systems so that
augmented responses are elicited upon later challenges
with either the same or somewhat diﬀerent stimuli
(Tilders and Schmidt, 1998). As a result, these treat-
ments do not only have immediate repercussions, but
may exert long-lasting neurochemical consequences,
which may impact on behavioural processes.
Several sources of evidence are, in fact, consistent
with the supposition that activation of the inﬂamma-
tory response system contributes to depression. For
instance, depressive illness has been associated with
increased levels of several cytokines and their soluble
receptors (Maes, 1999), endotoxin challenge elicits
signs of depression in both animals and human studies
(Reichenberg et al., 2001; Yirmiya et al., 1999), and such
eﬀects in animals are attenuated by tricyclic anti-
depressant treatments (Shen et al., 1999; Yirmiya et al.,
1999). Similarly, immunotherapy (IL-2 and IFN-a) has
been shown to elicit depressive symptoms (Capuron
et al., 2001) that are attenuated by antidepressant
medication (Musselman et al., 2001). Clearly the be-
havioural tests are still somewhat limited, but coupled
with the neurochemical ﬁndings, a prima-facie case
exists supporting a cytokine link in the aetiology of
some instances of depression. Of course, it ought to be
underscored that while activation of the inﬂammatory
response system may favour the development of de-
pressive symptoms, this does not necessarily imply that
instances of depression necessarily involve immune
activation.
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